Literature DB >> 10415066

Activation of mitogen-activated protein kinase regulates eotaxin-induced eosinophil migration.

S A Boehme1, S K Sullivan, P D Crowe, M Santos, P J Conlon, P Sriramarao, K B Bacon.   

Abstract

Eotaxin is a potent eosinophil chemoattractant that plays an important role in regulating eosinophil tissue levels both in healthy individuals and in diseases associated with significant eosinophil infiltrates, such as the allergic inflammation observed in asthma. Here, we demonstrate that treatment of eosinophils with eotaxin induces the phosphorylation of the mitogen-activated protein kinases (MAPKs) p42 and p44, leading to kinase activation. Blockade of MAPK activation by the MAPK kinase inhibitor PD98059 leads to a dramatic decrease in eotaxin-induced eosinophil rolling in vivo and chemotaxis in vitro. This blockade in the leukocyte migration process is consistent with the observed inhibition of actin polymerization and rearrangement within the eosinophil following treatment with MAPK inhibitor. It is suggested, therefore, that the intrinsic mechanism of eotaxin-induced eosinophil rolling and migration involves activation of the p42/p44 MAPK, possibly through regulation of the cytoskeletal rearrangements necessary for chemotaxis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415066

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

Review 1.  Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases.

Authors:  Adam P Curnock; Marisa K Logan; Stephen G Ward
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

2.  Evaluation of signal transduction pathways in chemoattractant-induced human monocyte chemotaxis.

Authors:  J S Fine; H D Byrnes; P J Zavodny; R W Hipkin
Journal:  Inflammation       Date:  2001-04       Impact factor: 4.092

3.  Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytes.

Authors:  Vitaliy Starosta; Konrad Pazdrak; Istvan Boldogh; Tetyana Svider; Alexander Kurosky
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

4.  Toward the Proteome of the Human Peripheral Blood Eosinophil.

Authors:  Christof Straub; Konrad Pazdrak; Travis W Young; Susan J Stafford; Zheng Wu; John E Wiktorowicz; Anthony M Haag; Robert D English; Kizhake V Soman; Alexander Kurosky
Journal:  Proteomics Clin Appl       Date:  2009       Impact factor: 3.494

5.  Regulation of eosinophil recruitment and allergic airway inflammation by heparan sulfate proteoglycan (HSPG) modifying enzymes.

Authors:  Xiao Na Ge; Idil Bastan; Sung Gil Ha; Yana G Greenberg; Jeffrey D Esko; Savita P Rao; P Sriramarao
Journal:  Exp Lung Res       Date:  2018-04-05       Impact factor: 2.459

6.  Regulation of Eosinophil Recruitment and Allergic Airway Inflammation by Tropomyosin Receptor Kinase A.

Authors:  Mythili Dileepan; Xiao Na Ge; Idil Bastan; Yana G Greenberg; Yuying Liang; P Sriramarao; Savita P Rao
Journal:  J Immunol       Date:  2019-12-23       Impact factor: 5.422

7.  Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists.

Authors:  Elena Riboldi; Giada Frascaroli; Pietro Transidico; Walter Luini; Sergio Bernasconi; Francesca Mancini; Angelo Guglielmotti; Claudio Milanese; Mario Pinza; Silvano Sozzani; Alberto Mantovani
Journal:  Br J Pharmacol       Date:  2003-08-18       Impact factor: 8.739

8.  Cryptotanshinone inhibits chemotactic migration in macrophages through negative regulation of the PI3K signaling pathway.

Authors:  M-J Don; J-F Liao; L-Y Lin; W-F Chiou
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

9.  Ligand-based molecular design of 4-benzylpiperidinealkylureas and amides as CCR3 antagonists.

Authors:  Vaibhav Jain; Ashish Pandey; Shikhar Gupta; C Gopi Mohan
Journal:  J Mol Model       Date:  2009-12-04       Impact factor: 1.810

10.  Primary prevention of allergic diseases: current concepts and mechanisms.

Authors:  Kerstin Gerhold; Yasemin Darcan; Eckard Hamelmann
Journal:  Allergy Asthma Clin Immunol       Date:  2007-12-15       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.